Compare Roblox Corp (RBLX) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? Roblox Corp trades at $46.91 (market cap $35.37B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Roblox Corp is far larger — about 4.7× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roblox Corp for 94 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| RBLX | SYRE | |
|---|---|---|
Market Cap | $35.37B | $7.52B |
Volume | 6,569,814 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $138.56 | $108.92 |
52-Week Low | $35.54 | $22.18 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $34.19B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roblox (RBLX) trades at $47.54, down 4.13% today amid mixed technical signals and analyst concerns about bookings growth. The stock shows strong revenue growth (2025: $4.89B, up 36% year-over-year) but remains unprofitable with a -17.61% net margin. Recent technical analysis indicates bullish moving averages but neutral oscillators, with key resistance at $50-$52. The company continues to beat earnings expectations, with Q2 2026 EPS of -$0.26 beating estimates by 24%.
Investment outlook balances strong user engagement and AI-driven creator tools against persistent profitability challenges. Analyst consensus sits at $51.35 with 42% buy ratings, though recent Jefferies downgrade to Underperform highlights concerns about valuation sustainability. Key risks include decelerating bookings growth and high P/B ratio of 232.69, while opportunities lie in AI-powered platform expansion and $3 billion buyback program.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
